Seven-year safety and efficacy of the unrestricted use of drug-eluting stents in saphenous vein bypass grafts

• Published in: Catheterization and cardiovascular interventions Vol. 79; no. 6; pp. 912 - 918
• Main Authors: Nauta, Sjoerd T., Van Mieghem, Nicolas M., Magro, Michael, Deckers, Jaap W., Simsek, Cihan, Jan Van Geuns, Robert, Van Der Giessen, Wim J., De Jaegere, Peter, Regar, Evelyn, Van Domburg, Ron T., Serruys, Patrick W.
• Format: Journal Article
• Language: English
• Published: Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.05.2012
• Subjects: Aged; Angioplasty, Balloon, Coronary - adverse effects; Angioplasty, Balloon, Coronary - instrumentation; Angioplasty, Balloon, Coronary - mortality; cardiology; Cardiovascular Agents - administration & dosage; Chi-Square Distribution; Constriction, Pathologic; Coronary Angiography; coronary artery bypass; Coronary Artery Bypass - adverse effects; Coronary Artery Bypass - mortality; Drug-Eluting Stents; Female; Graft Occlusion, Vascular - diagnostic imaging; Graft Occlusion, Vascular - etiology; Graft Occlusion, Vascular - mortality; Graft Occlusion, Vascular - therapy; Humans; Kaplan-Meier Estimate; Male; Metals; Middle Aged; Myocardial Infarction - etiology; Netherlands; Paclitaxel - administration & dosage; Predictive Value of Tests; Proportional Hazards Models; Prosthesis Design; Risk Assessment; Risk Factors; Saphenous Vein - diagnostic imaging; Saphenous Vein - transplantation; Sirolimus - administration & dosage; Stents; survivors; Time Factors; Treatment Outcome
• ISSN: 1522-1946; 1522-726X
• DOI: 10.1002/ccd.23145

Objectives: The aim was to investigate the 7‐year clinical outcomes of patients treated with either drug‐eluting stents (DES) or bare‐metal stents (BMS) for saphenous vein graft disease (SVG). Background: Atherosclerotic disease in SVG has several peculiarities which make it difficult to extrapolate outcomes of the use of DES as compared to BMS, from outcomes observed in native coronary arteries. To date no long‐term safety and efficacy results for DES in SVG have been published. Methods: Between January, 2000 and December, 2005 a total of 250 consecutive patients with saphenous vein graft disease were sequentially treated with DES (either sirolimus‐ or paclitaxel‐eluting stents) or with BMS. Yearly follow‐up was performed. Results: At 87 months (7.25 years), a total of 101 patients died (58 [46%] in the BMS group and 43 [42%] in the DES group, P‐value= 0.4). There was no significant difference in the combined endpoint mortality or myocardial infarction. Cumulative target vessel revascularisation (TVR) was higher in the BMS group compared to the DES group (41% vs. 29%, respectively; adjusted hazard ratio [HR] 0.63, 95% confidence interval [CI]: 0.39–1.0). The cumulative incidence of major adverse cardiac events was 73% vs. 68% in the BMS and DES groups, respectively (adjusted HR 0.93, 95% CI: 0.67–1.3). Conclusions: In the present study, the unrestricted use of DES for SVG lesions appeared safe and effective up to 7.25 years‐ and the use of DES resulted in a clinically relevant lower rate of TVR. © 2011 Wiley Periodicals, Inc.